Cantor Fitzgerald Predicts TG Therapeutics FY2026 Earnings

TG Therapeutics, Inc. (NASDAQ:TGTX) – Analysts at Cantor Fitzgerald issued their FY2026 earnings estimates for TG Therapeutics in a research report issued on Monday, June 9th. Cantor Fitzgerald analyst P. Agrawal anticipates that the biopharmaceutical company will post earnings of $1.80 per share for the year. The consensus estimate for TG Therapeutics’ current full-year earnings is $0.08 per share.

TG Therapeutics (NASDAQ:TGTX) last posted its quarterly earnings results on Wednesday, May 7th. The biopharmaceutical company reported $0.03 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.19 by ($0.16). The company had revenue of $120.86 million during the quarter, compared to analyst estimates of $117.07 million. TG Therapeutics had a negative net margin of 5.42% and a negative return on equity of 8.32%. The company’s revenue was up 90.4% on a year-over-year basis. During the same period in the prior year, the company earned ($0.07) earnings per share.

Several other analysts have also recently issued reports on the stock. HC Wainwright reaffirmed a “buy” rating and issued a $55.00 price target on shares of TG Therapeutics in a report on Tuesday, March 4th. Wall Street Zen raised shares of TG Therapeutics from a “sell” rating to a “hold” rating in a report on Tuesday, March 4th. Two analysts have rated the stock with a hold rating and four have issued a buy rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $40.80.

TG Therapeutics Trading Down 1.0%

TGTX opened at $39.43 on Tuesday. The stock has a market capitalization of $6.26 billion, a PE ratio of -394.26 and a beta of 1.94. The firm’s fifty day moving average price is $37.21 and its 200 day moving average price is $34.75. The company has a debt-to-equity ratio of 1.27, a current ratio of 4.59 and a quick ratio of 3.91. TG Therapeutics has a 12-month low of $15.63 and a 12-month high of $46.48.

Institutional Trading of TG Therapeutics

Institutional investors have recently made changes to their positions in the stock. Vermillion Wealth Management Inc. acquired a new stake in shares of TG Therapeutics during the fourth quarter worth approximately $30,000. NBC Securities Inc. boosted its holdings in shares of TG Therapeutics by 82,300.0% during the first quarter. NBC Securities Inc. now owns 824 shares of the biopharmaceutical company’s stock worth $32,000 after purchasing an additional 823 shares during the period. Golden State Wealth Management LLC boosted its holdings in shares of TG Therapeutics by 100.0% during the first quarter. Golden State Wealth Management LLC now owns 866 shares of the biopharmaceutical company’s stock worth $34,000 after purchasing an additional 433 shares during the period. SVB Wealth LLC acquired a new stake in shares of TG Therapeutics during the first quarter worth approximately $37,000. Finally, Quadrant Capital Group LLC boosted its holdings in shares of TG Therapeutics by 137.1% during the fourth quarter. Quadrant Capital Group LLC now owns 1,686 shares of the biopharmaceutical company’s stock worth $51,000 after purchasing an additional 975 shares during the period. 58.58% of the stock is currently owned by institutional investors and hedge funds.

About TG Therapeutics

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.